Form 4: CervoMed Director Sylvie Gregoire Receives Stock Options

Director Sylvie Gregoire was granted 8,150 stock options following her election to the CervoMed Inc. board of directors.

Summary

• Sylvie Gregoire, a director and 10% owner of CervoMed Inc., was granted 8,150 stock options on June 8, 2026.
• The grant was issued in connection with her election to the board of directors at the 2026 Annual Meeting of Stockholders.
• The options have an exercise price of $2.91 per share.
• The options vest in 1/12th increments monthly over a one-year period, starting June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation practice for non-employee directors.

Negatives

• Minor dilution of existing shareholders upon the potential exercise of these options.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest monthly over one year, provided the director remains in service, with an expiration date of June 8, 2036.

Management Comments

• The grant is in accordance with the terms of the Issuer's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that equity grants for board members are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The use of 12-month vesting schedules for director equity is consistent with standard practices for small-cap biotech firms.
• The grant size is typical for non-employee director compensation packages in companies of similar market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact.
• Director: Increased equity stake in the company.

Next Steps

• Monthly vesting of options beginning June 30, 2026.

Key Dates

Keywords

CervoMed, CRVO, Form 4, Director Compensation, Stock Options, Insider Transaction